Reuters logo
BRIEF-DBV Technologies peanut allergy treatment fails to meet main goal in late-stage study
October 20, 2017 / 9:42 PM / a month ago

BRIEF-DBV Technologies peanut allergy treatment fails to meet main goal in late-stage study

Oct 20 (Reuters) - Dbv Technologies Sa

* DBV Technologies announces topline results of phase III clinical trial in peanut-allergic patients four to 11 years of age‍​

* DBV Technologies - topline results show statistically significant response with a favorable tolerability profile

* DBV Technologies - primary endpoint did not reach 15% lower bound of CI that was proposed in study’s statistical analysis plan‍​

* DBV Technologies - DBV will continue ongoing discussions with FDA, and plans to proceed with the BLA preparation process Source text (bit.ly/2xbQD5H) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below